Pricing Log in Create free account
Sunday 11 October 2026 Export all AMGN data to Excel Powerpack

Amgen Inc.

AMGN Healthcare Drug Manufacturers General

Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.

414.87 7.43 +1.82%
Market cap
$220.3B
P/E
25.6×
Fwd P/E
22.7×
Dividend yield
2.40%
F-score
7/9
Altman Z
1.69
Beneish M
−2.27
Dividend safety
56/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Amgen Inc. (AMGN) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Jun 30, 2026 P1I2: 13 added · 6 removed · 63 modified
P2I1A: 26 added · 9 removed · 24 modified
8-K Aug 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jul 29, 2026 1.05 Material cybersecurity incident
8-K May 19, 2026 5.07 Submission of matters to a vote of security holders
8-K May 19, 2026 5.02 Departure or appointment of directors or officers Officer departure
10-Q Mar 31, 2026
8-K Apr 30, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 22, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
8-K Feb 17, 2026 1.01 Entry into a material definitive agreement; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 32 added · 28 removed · 84 modified
1A: 9 added · 9 removed · 99 modified
7: 30 added · 18 removed · 74 modified
8-K Feb 3, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 30, 2026 1.02 Termination of a material definitive agreement; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 4, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
10-K Dec 31, 2024

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.